News
Why Hims & Hers Health Stock Just Dropped
Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines.
Hims & Hers Health (NYSE:HIMS) Misses Q2 Revenue Estimates, Stock Drops 12%
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter’s revenue to be around $580 million,
Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.
Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...
Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...
Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...
Investor's Business Daily on MSN5h
IBD 50's Hims & Hers Plummets By Double Digits. Is The Obesity Business In Trouble?
Hims stock crashed late Monday after the obesity kingpin lagged Wall Street's second-quarter sales forecasts, though profit ...
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop. Find out why I maintain a 'Buy' rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback